Menu
/REGISTER
Montecito
FMB
Loading...
You are here:  Home  >  Biotech  >  Current Article

Amgen tackles rheumatoid arthritis with third biosimilar to get FDA OK

By   /   Friday, December 13th, 2019  /   Comments Off on Amgen tackles rheumatoid arthritis with third biosimilar to get FDA OK

    Print       Email
Thousand Oaks biotech giant Amgen entered a crowded field with its rheumatoid arthritis biosimilar Avsola, where it will tussle with three competitors for some $6 billion in annual sales. The move is the latest in its biosimilar strategy, playing to the biotech giant’s strength in the anti-inflammatory field and targeting newer patients in a growing…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Tri-county performers struggle as audiences forbidden

Read More →